Skip to main content

Table 1 Input parameters

From: Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada

Parameters

Age (Years)

Source(s)/Assumption

 

0–2

2–4

5–17

18–64

65+

 

Incidence (per 100,000)

      

  Bacteremia

14.77

10.62

6.74

43.67

87.07

[18]

  Meningitis

0.52

0.37

0.24

1.54

3.07

 

  Inpatient PNE

1,135.13

380.99

170.84

102.76

1,343.40

[19–21]

  Outpatient PNE

874.77

460.69

514.63

55.35

63.31

 

  Mild AOM

13,762.21

13,811.12

10,486.67

0.00

0.00

[22]

  Moderate/severe AOM

2,147.86

2,155.49

1,636.65

0.00

0.00

 

Serotype coverage

      

  PCV10

0.18

0.23

0.26

0.28

0.22

[23]

  PCV13

0.61

0.68

0.42

0.55

0.55

 

Mortality

      

  Bacteremia

0.01

0.003

0.003

0.07

0.11

[26–28]

  Meningitis

0.02

0.003

0.003

0.07

0.11

 

  Inpatient PNE

0.01

0.003

0.003

0.07

0.11

 

Direct medical costs

      

  Bacteremia

$10,578.71

$3,379.85

$9,768.95

$13,559.64

$11,913.26

[19, 51]

  Meningitis

$48,382.04

$24,615.09

$61,114.72

$22,409.11

$11,782.22

 

  Inpatient PNE

$3,450.13

$2,149.73

$10,305.00

$9,606.02

$8,370.61

 

  Outpatient PNE

$138.18

$69.09

$184.24

$126.66

$103.63

 

  Mild AOM

$95.30

$47.65

$71.47

$0.00

$0.00

 

  Moderate/severe AOM

$95.30

$47.65

$71.47

$0.00

$0.00

 

Utilities

0.97

0.97

0.97

0.88

0.82

[54]

  1. AOM acute otitis media; PCV10 10-valent pneumococcal conjugate vaccine; PCV13 13-valent pneumococcal conjugate vaccine; PNE pneumonia.